Combination of sodium-glucose cotransporter type 2 inhibitors and urate-lowering therapy in people with gout from a specialist clinic: a retrospective, single-center observational study.

ABSTRACT: To evaluate the effectiveness of sodium-glucose cotransporter type 2 (SGLT2) inhibitors combined with traditional urate-lowering therapy (ULT) in people with gout, we conducted a retrospective, single-center observational study in a crystal arthritis clinic. Primary outcomes were reduction in serum urate (SU) levels and achievement of SU targets (<6 mg/dL and <5 mg/dL). We also compared prescribed allopurinol doses versus Easy-Allo-predicted doses and evaluated changes in diuretic use. The sample comprised 46 individuals (median age 75 years; 82.6% men) with a high prevalence of long-standing gout and comorbidities. Combined treatment was associated with a median SU reduction of 0.85 mg/dL (95% CI -1.7 to -0.1, p = 0.001). This effect was more pronounced in individuals without prior

SUBMITTER: Domenech-Serrano J 

PROVIDER: S-EPMC12832974 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature